Magnetic Tandem Apoptosis for Overcoming Multidrug-Resistant Cancer

被引:45
作者
Cho, Mi Hyeon [1 ,2 ,3 ]
Kim, Seulmi [1 ,2 ,3 ]
Lee, Jae-Hyun [1 ,2 ,3 ]
Shin, Tae-Hyun [1 ,2 ,3 ]
Yoo, Dongwon [1 ,2 ]
Cheon, Jinwoo [1 ,2 ,3 ]
机构
[1] Inst for Basic Sci Korea, Ctr Nanomed, Seoul 03722, South Korea
[2] Yonsei Univ, Yonsei IBS Inst, Seoul 03722, South Korea
[3] Yonsei Univ, Dept Chem, Seoul 03722, South Korea
关键词
Magnetic nanoparticle; magnetic field; tandem activation; multidrug-resistant cancer; apoptosis; P-GLYCOPROTEIN; DRUG-RESISTANCE; NANOPARTICLES; OVARIAN; DEATH; CELLS; INHIBITION; CISPLATIN; THERAPY; TRAIL;
D O I
10.1021/acs.nanolett.6b03122
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Multidrug resistance (MDR) is a leading cause of failure in current chemotherapy treatment and constitutes a formidable challenge in therapeutics. Here, we demonstrate that a nanoscale magnetic tandem apoptosis trigger (m-TAT), Which consists of a magnetic nanoparticle and chemodrug (e.g., doxorubicin), can completely remove MDR cancer cells in both in vitro and in vivo systems. m-TAT simultaneously activates extrinsic and intrinsic apoptosis signals in a synergistic fashion and downregulates the drug efflux pump (e.g., P-glycoprotein) which is one of the main causes of MDR. The tandem apoptosis strategy uses low level of chemodrug (in the nanomolar (nM) range) to eliminate MDR cancer cells. We further demonstrate that apoptosis of MDR cancer cells can be achieved in a spatially selective manner with single-cell level precision. Our study indicates that nanoscale tandem activation of convergent signaling pathways is a new platform concept to overcome MDR with high efficacy and specificity.
引用
收藏
页码:7455 / 7460
页数:6
相关论文
共 31 条
[1]   Targeting death and decoy receptors of the tumour-necrosis factor superfamily [J].
Ashkenazi, A .
NATURE REVIEWS CANCER, 2002, 2 (06) :420-430
[2]  
Cho MH, 2012, NAT MATER, V11, P1038, DOI [10.1038/NMAT3430, 10.1038/nmat3430]
[3]   Cancer Therapy Death by magnetism [J].
Dobson, Jon .
NATURE MATERIALS, 2012, 11 (12) :1006-1008
[4]   Overcoming multidrug resistance of small-molecule therapeutics through conjugation with releasable octaarginine transporters [J].
Dubikovskaya, Elena A. ;
Thorne, Steve H. ;
Pillow, Thomas H. ;
Contag, Christopher H. ;
Wender, Paul A. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (34) :12128-12133
[5]   Antibody-Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies [J].
Ducry, Laurent ;
Stump, Bernhard .
BIOCONJUGATE CHEMISTRY, 2010, 21 (01) :5-13
[6]   Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy [J].
Fulda, S. ;
Debatin, K. -M .
ONCOGENE, 2006, 25 (34) :4798-4811
[7]   Multidrug resistance in cancer: Role of ATP-dependent transporters [J].
Gottesman, MM ;
Fojo, T ;
Bates, SE .
NATURE REVIEWS CANCER, 2002, 2 (01) :48-58
[8]   Nanoscale Metal-Organic Frameworks for the Co-Delivery of Cisplatin and Pooled siRNAs to Enhance Therapeutic Efficacy in Drug-Resistant Ovarian Cancer Cells [J].
He, Chunbai ;
Lu, Kuangda ;
Liu, Demin ;
Lin, Wenbin .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2014, 136 (14) :5181-5184
[9]   Cancer drug resistance: an evolving paradigm [J].
Holohan, Caitriona ;
Van Schaeybroeck, Sandra ;
Longley, Daniel B. ;
Johnston, Patrick G. .
NATURE REVIEWS CANCER, 2013, 13 (10) :714-726
[10]   Nanoparticle-based combination therapy toward overcoming drug resistance in cancer [J].
Hu, Che-Ming Jack ;
Zhang, Liangfang .
BIOCHEMICAL PHARMACOLOGY, 2012, 83 (08) :1104-1111